文献速递肝病

直接比较FibroMeterV2G与ELF评分在NAFLD肝纤维化诊断中的准确性

Direct comparison of the specialised blood fibrosis tests FibroMeterV2G and Enhanced Liver Fibrosis score in patients with non-alcoholic fatty liver disease from tertiary care centres.
PubMed 文献 · Aliment Pharmacol Ther · 2019-10-15

结果显示ELF和FibroMeterV2G的AUROC显著高于NFS和FIB4,但两者之间无显著差异,且两者序贯活检算法均具有高诊断准确性。

要点

  • ELF和FibroMeterV2G对晚期纤维化的诊断准确性相当,且均优于NFS和FIB4。
  • 使用ELF或FibroMeterV2G后序贯肝活检的算法可获得90%敏感性和90%特异性。
  • ELF算法下肝活检率为45.3%,FibroMeterV2G为39.3%,两者无显著差异。

核心结论

  • 在三级中心NAFLD患者中,ELF和FibroMeterV2G对晚期肝纤维化的诊断准确性相同,且均优于简单血液检测FIB4和NFS。

主要发现

  • 晚期纤维化的AUROC:ELF为0.793 ± 0.022,FibroMeterV2G为0.804 ± 0.021,NFS为0.722 ± 0.025,FIB4为0.739 ± 0.024。
  • ELF和FibroMeterV2G的AUROC显著高于NFS(P < .010)和FIB4(P < .020)。
  • ELF与FibroMeterV2G之间晚期纤维化的AUROC和Obuchowski指数无显著差异。
  • 直接纤维化标志物(透明质酸、PIIINP、TIMP-1、α2-巨球蛋白)与NFS和FIB4的AUROC无显著差异。
  • 序贯算法(先ELF或FibroMeterV2G,诊断不确定时行肝活检)对晚期纤维化的敏感性90%、特异性90%、阴性预测值93%、阳性预测值85%、正确分类率90%。

临床怎么用

  • 在三级中心NAFLD患者中,可选用ELF或FibroMeterV2G无创评估晚期纤维化,其准确性优于FIB4和NFS。
  • 采用先ELF或FibroMeterV2G、诊断不确定时行肝活检的序贯算法,可达到高诊断准确性并避免部分肝活检。

局限性

  • 研究人群为三级中心活检证实的NAFLD患者,结果可能不适用于其他医疗场景。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The Enhanced Liver Fibrosis score (ELF) and the FibroMeterV2G are two specialized blood fibrosis tests which include direct markers of liver fibrosis. They have been shown to be more accurate than the simple blood fibrosis tests FIB4 and the non-alcoholic fatty liver disease (NAFLD) fibrosis score (NFS). AIMS: To directly compare the accuracies of ELF and FibroMeterV2G for the non-invasive diagnosis of liver fibrosis in NAFLD. METHODS: Four hundred and seventeen patients with biopsy-proven NAFLD were enrolled from two tertiary care centres. Four blood fibrosis tests were calculated: ELF, FibroMeterV2G , NFS, and FIB4. Advanced fibrosis F3/4 on liver biopsy (NASH CRN scoring) was the primary endpoint. RESULTS: Areas under the receiver operating characteristic (AUROC) curve for advanced fibrosis were not significantly different between the direct markers of liver fibrosis (hyaluronate, PIIINP, TIMP-1, alpha2-macroglobulin) and the simple blood fibrosis tests NFS and FIB4. ELF (0.793 ± 0.022) and FibroMeterV2G (0.804 ± 0.021) had significantly higher AUROC than NFS (0.722 ± 0.025, P < .010) and FIB4 (0.739 ± 0.024, P < .020). AUROC for advanced fibrosis and Obuchowski index were not significantly different between ELF and FibroMeterV2G . Algorithms using first ELF or FibroMeterV2G and then liver biopsy in case of undetermined diagnosis provided high diagnostic accuracy for advanced fibrosis: 90% sensitivity, 90% specificity, 93% negative predictive value, 85% positive predictive value, and 90% correct classification. In these algorithms, the rate of liver biopsy was 45.3% with ELF versus 39.3% with FibroMeterV2G (P = .065). CONCLUSIONS: ELF and FibroMeterV2G have equal accuracy and perform better than the simple FIB4 and NFS tests for the non-invasive diagnosis of advanced liver fibrosis in patients with NAFLD from tertiary care centres.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Guillaume M, Moal V, Delabaudiere C, et al. Direct comparison of the specialised blood fibrosis tests FibroMeterV2G and Enhanced Liver Fibrosis score in patients with non-alcoholic fatty liver disease from tertiary care centres. Aliment Pharmacol Ther. 2019. PMID: 31617224. doi:10.1111/apt.15529

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。